

- **Name:** Ji-Won Kim
 - **Current Position & Affiliation:** Associate Professor
Division of Hematology and Medical Oncology
Seoul National University Bundang Hospital
 - **Country:** Republic of Korea
-

• **Educational Background:**

- 2014 – 2021: Ph.D. in Clinical Medical Sciences, Seoul National University College of Medicine, Seoul, Korea
- 2009 – 2014: M.S. in Molecular Oncology, Seoul National University College of Medicine, Seoul, Korea
- 1999 – 2005: M.D., Seoul National University College of Medicine, Seoul, Korea

• **Professional Experience:**

- Mar. 2021 – Present: Associate Professor, Seoul National University Bundang Hospital, Seongnam, Korea
- Mar. 2015 – Feb. 2021: Assistant Professor Seoul National University Bundang Hospital, Seongnam, Korea
- May 2013 – Feb. 2015: Clinical Fellow, Seoul National University Hospital, Seoul, Korea
- Apr. 2010 – Apr. 2013: Public Health Doctor
- Mar. 2006 – Feb. 2010: Resident Physician, Seoul National University Hospital, Seoul, Korea
- Mar. 2005 – Feb. 2006: Intern, Seoul National University Hospital, Seoul, Korea

• **Professional Organizations:**

- American Society of Clinical Oncology (ASCO): Full Member
- Korea Genome Organization (KOGO): Member
- American Association for Cancer Research (AACR): Member
- Korean Cancer Study Group (KCSG): Member
- Korean Society of Medical Oncology (KSMO): Member
- Korean Cancer Association: Member
- Korean Association of Internal Medicine: Member
- Korean Medical Association (KMA): Member

• **Main Scientific Publications:**

1. Kim SA, Park H, Kim KJ, **Kim JW (corresponding author)**, Sung JH, Nam M, Lee JH, Jung EH, Suh KJ, Lee JY, Kim SH, Lee JO, Kim JW, Kim YJ, Kim JH, Bang SM, Lee JS, Lee KW. Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer. Sci Rep. 2021 Dec 10;11(1):23803.
2. Kim SA, Park H, Kim KJ, **Kim JW (corresponding author)**, Sung JH, Nam M, Lee JH, Jung EH, Suh KJ, Lee JY, Kim SH, Lee JO, Kim JW, Kim YJ, Kim JH, Bang SM, Lee JS, Lee KW.

15th Annual Meeting of the Korean Society of Medical Oncology & 2022 International Conference

- Cetuximab resistance induced by hepatocyte growth factor is overcome by MET inhibition in KRAS, NRAS, and BRAF wild-type colorectal cancers. *J Cancer Res Clin Oncol*. 2021 Dec 1. doi: 10.1007/s00432-021-03872-4. Epub ahead of print.
3. Kim KJ, **Kim JW (co-first author)**, Sung JH, Suh KJ, Lee JY, Kim SH, Lee JO, Kim JW, Kim YJ, Kim JH, Bang SM, Lee JS, Kim HK, Lee KW. PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer. *Sci Rep*. 2020 Jul 23;10(1):12308.
 4. Kim SA, **Kim JW (corresponding author)**, Suh KJ, Chang W, Kim JW, Oh HK, Cho JY, Kim DW, Cho S, Kim JH, Kim K, Kang SB, Jheon S, Lee KW. Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases. *J Cancer Res Clin Oncol*. 2020 Sep;146(9):2399-2410.
 5. Nam AR, **Kim JW (co-first author)**, Park JE, Bang JH, Jin MH, Oh DY, Bang YJ. Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer. *Cancer Res Treat*. 2019 Jul;51(3):886-900.